Clever Culture Systems Secures $2.6 Million Funding Package to Develop New Benchtop APAS® Revolution System

Aakashdeep

03 November 2026 08:45 PM AEDT

Clever Culture Systems Secures $2.6 Million Funding Package to Develop New Benchtop APAS® Revolution System

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Clever Culture Systems (ASX:CC5) has announced commitments for a $2.6 million funding package to accelerate development of APAS® Revolution, a new benchtop configuration of its Automated Plate Assessment System technology designed for smaller sterile pharmaceutical manufacturing facilities.

Key Points

Funding package of $2.6 million (before costs) comprises a $1.0 million capital raise and a $1.6 million unsecured loan due for repayment on 30 November 2027
APAS® Revolution targets smaller sterile drug manufacturing facilities not served by existing APAS® Independence automation
The company estimates the funding package expands the total addressable market for APAS® technology by approximately 50%, from $2.8 billion to $4.3 billion
Pre-production instruments are expected to be released to customers for evaluation in the 2027 calendar year, with final product launch expected in the first half of 2028

APAS® Revolution Funding Structure and Development Terms

The $2.6 million funding package secured by Clever Culture Systems combines a targeted $1.0 million capital raise with a $1.6 million unsecured loan. The unsecured loan is due for repayment on 30 November 2027. According to the filing, the company characterised the mix of equity and debt as a capital-efficient funding approach, supported by an improved outlook for sales over the next 12 months and beyond. The product development project is to be completed with an external engineering partner, which had not yet been selected at the time of the filing. The company stated it expects payback in under two years from product launch.

APAS® Revolution System Design and Market Addressability

APAS® Revolution is described in the filing as a benchtop system designed specifically for small to medium size, lower-volume sterile drug manufacturing facilities globally. The company estimates a total addressable market exceeding 3,400 APAS® Revolution instruments, in addition to the 2,300 APAS® Independence instruments already identified. The new system will leverage the proven APAS® imaging station, plate-gripping system and validated AI-powered analysis modules used in the commercially released APAS® Independence instrument. The filing states this approach lowers development cost, reduces the development timeline, and lowers development risk compared with building an entirely new platform.

Commercial Context Including PSC Biotech Sales Agency Appointment

The filing references the recent appointment of PSC Biotech as a sales agent for APAS® Independence in North America, Canada and Singapore as a further commercialisation building block ahead of the APAS® Revolution product launch. According to the filing, PSC Biotech has an established presence in pharmaceutical validation, engineering and regulatory services. The filing also states that the company's existing global pharmaceutical customers represent a significant opportunity to establish an early pipeline for APAS® Revolution ahead of launch, given their prior investment in evaluating and validating APAS® Independence technology.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.